Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 5/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.45 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29397635 | 1.00 | KDM4E (0.57) | KDM4EALDH1A1LMNAHTTL3MBTL1 | |
| SCHEMBL22912726 | 0.89 | EGFR (0.56) | KDM4EALDH1A1LMNAHTTL3MBTL1 | |
| SCHEMBL29395745 | 0.89 | EGFR (0.56) | KDM4EALDH1A1LMNAHTTL3MBTL1 | |
| SCHEMBL22912783 | 0.86 | KDM4E (0.57) | KDM4EALDH1A1LMNAHTTL3MBTL1 | |
| SCHEMBL22963779 | 0.84 | KDM4E (0.56) | KDM4EALDH1A1LMNAHTTL3MBTL1 | |
| SCHEMBL29396732 | 0.84 | KDM4E (0.62) | KDM4EALDH1A1LMNAHTTL3MBTL1 | |
| SCHEMBL22912779 | 0.84 | KDM4E (0.62) | KDM4EALDH1A1LMNAHTTL3MBTL1 | |
| SCHEMBL29396283 | 0.84 | KDM4E (0.56) | KDM4EALDH1A1LMNAHTTL3MBTL1 | |
| SCHEMBL30908290 | 0.79 | KDM4E (0.61) | KDM4EALDH1A1LMNAHTTL3MBTL1 | |
| SCHEMBL6304842 | 0.78 | KDM4E (0.70) | KDM4EALDH1A1LMNAHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606555-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2026-04-21 | — | — | US | disclosed |
| EP-4529952-A2 | PARP1 INHIBITORS | Astrazeneca AB (SE) | 2025-04-02 | — | — | EP | disclosed |
| EP-3999506-B1 | PARP1 INHIBITORS | ASTRAZENECA AB (SE) | 2025-01-15 | — | — | EP | disclosed |
| US-20230372527-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2023-11-23 | — | — | US | disclosed |
| US-20230372527-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2023-11-23 | — | — | US | disclosed |
| EP-4225314-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | AstraZeneca UK Limited (GB) | 2023-08-16 | — | — | EP | disclosed |
| CN-116348115-A | Combination of antibody-drug conjugate and PARP1 selective inhibitor | 阿斯利康(英国)有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20220227768-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2022-07-21 | — | — | US | disclosed |
| EP-3999506-A1 | PARP1 INHIBITORS | Astrazeneca AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| US-11325906-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2022-05-10 | — | — | US | disclosed |
| US-11325906-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2022-05-10 | — | — | US | disclosed |
| WO-2022074617-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022074617-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| CN-114144413-A | PARP1 inhibitors | 阿斯利康(瑞典)有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-20210040084-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| US-20210040084-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| WO-2021013735-A1 | PARP1 INHIBITORS | ASTRAZENECA AB (SE) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021013735-A1 | PARP1 INHIBITORS | ASTRAZENECA AB (SE) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040084-A1 | CHEMICAL COMPOUNDS | CYP11B2, CYP11B1, CYP4B1 | KDM4E 544/4885ALDH1A1 123/4885LMNA 2818/4885 |
| US-12606555-B2 | Chemical compounds | PARP1, PARP11, PARP12 | KDM4E 136/4885ALDH1A1 438/4885LMNA 676/4885 |
| US-20220227768-A1 | CHEMICAL COMPOUNDS | CYP11B2, CYP11B1, CYP4B1 | KDM4E 544/4885ALDH1A1 123/4885LMNA 2818/4885 |
| US-20230372527-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR | PARP12, PARP11, PARP1 | KDM4E 2263/4885ALDH1A1 1194/4885LMNA 2575/4885 |
| US-11325906-B2 | Chemical compounds | CYP11B2, CYP11B1, CYP4B1 | KDM4E 544/4885ALDH1A1 123/4885LMNA 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.